Fig. 3

Forest plot for primary efficacy outcome, secondary efficacy outcomes and safety outcomes, stratified by age. OR, odds ratio; HR, hazard ratio; SAE, severe adverse event; AE, adverse event; The effect of Xuesaitong therapy compared with placebo therapy on primary, secondary efficacy and safety outcomes were described in terms of event rates, HRs, ORs, and interaction terms. ^a Logistic or cox regression analysis was applied to estimate crude OR/HR. ^b Adjusted OR/HR was consequently estimated by adjusting the crude OR/HR for gender, the TOAST classification, baseline mRS score, baseline NIHSS score, and any other variables that displayed baseline inter-group differences. ^c Interaction P value was for the interaction between treatment and subgroup. A significant p-interaction value (< 0.05) indicated that the treatment effect was influenced by age. A Forest plot for functional independence (defined as a mRS of 0 to 2) and no or minimal disability (defined as a mRS of 0 to 1) within 3 and 12 months. B Forest plot for recurrent stroke and composite cerebrovascular events (including cerebral infarction, intracerebral hemorrhage, myocardial infarction, and vascular death), measured at 3 and 12 months. C Forest plot for safety outcomes within 3 months